Full history for every metric is available with a Kvantra account
Stock profile
Merrimack Pharmaceuticals, Inc. (MACK)
Current price
15.13 USD0.00%
Last close 28 May 2024Benchmarks
Key financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -2 | -2 | |||||
| Net profit | $m | -41 | -21 | -3 | -2 | -2 | -1 | - |
| EPS reported | $ | -0.08 | - | |||||
| Operating cashflow per share | $ | -0.11 | -0.11 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -0.11 | -0.11 | |||||
| Free cash flow | $m | -2 | -2 | |||||
| Net debt | $m | -19 | -244 | |||||
| Book value equity | $m | 19 | - | |||||
| Book value per share | $ | 1.31 | - | |||||
| Number of shares | m | 14.3 | 14.45 | |||||
| DPS (TTM paid) | $ | 30.20 | 0.00 |
Financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 10.23 | 11.55 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -125.99 | -90.31 | |||||
| EV/EBITDA LTM | x | 184.47 | 20.63 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -0.62% | -0.55% | |||||
| FCF Yield | % | -0.79% | -1.11% | |||||
| Quality | ||||||||
| ROE | % | -6.30% | -6.22% | |||||
| ROIC | % | -11.61% | -11.61% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | - | - | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | -5.95 | -5.95 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -9.84% | -108.99% | |||||
| Net debt/Equity | x | -1.01 | - | |||||
| Gross debt/equity | x | 0.00 | - | |||||
Company overview
Founded in 1993, Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
MA
Merrimack Pharmaceuticals, Inc. (MACK)
MACK · NASDAQ · Healthcare
15.13 USD0.00%
Benchmarks
Financialsin USD
20222023TTM
Total revenue $m000
Operating profit $m-2-2
Net profit $m-2-1-
EPS reported $-0.08-
About
Founded in 1993, Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free